Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population

Optimizing refolding condition for recombinant tissue plasminogen activator

Low molecular size additives such as L-arginine and the redox compounds have been used both in the culturemedium and in vitro refolding to increase recombinant proteins production. Additives increase proteinrefolding and yield of active proteins by suppressing aggregate formation or enhancing refolding process.In this work, a comparative study was performed on refolding of rec...

Defining intravenous recombinant tissue plasminogen activator failure.

Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial.

BACKGROUND AND PURPOSE The publication of the European Cooperative Acute Stroke Study (ECASS III) expanded the treatment time to thrombolysis for acute ischemic stroke from 3 to 4.5 hours from symptom onset. The impact of the expanded time window on treatment rates has not been comprehensively evaluated in a population-based study. METHODS All patients with an ischemic stroke presenting to an...

Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study.

BACKGROUND AND PURPOSE Acute ischemic stroke patients are infrequently treated with recombinant tissue plasminogen activator (rtPA). We present unique population-based data regarding the eligibility of ischemic stroke patients for rtPA treatment. METHODS All ischemic strokes presenting to an emergency department (ED) within a biracial population of 1.3 million were identified. The patient was...

4.5-hour time window for intravenous thrombolysis with recombinant tissue-type plasminogen activator is established firmly.

This is a clear case. Yes! The patient should immediately be treated with the standard dose of rt-PA as per approval in Europe and many other countries on this planet. After the results of all pooled analyses (National Institute of Neurological Disorders and Stroke [NINDS], European Cooperative Acute Stroke Study 1–2 [ECASS 1–2], Alteplase Thrombolysis for Acute Noninterventional Therapy in Isc...